FTSE 100 Climbs: Mining Stocks Fall, Experian Gains

The FTSE 100 has gained 0.2% on Friday morning, supported by corporate updates, while broader European markets also gained. Germany’s DAX has advanced 0.9% and France’s CAC 40 has risen 0.4%.

Experian is the index’s top performer after the company announced a $1 billion share repurchase program. The global data and technology group said it “continues to trade strongly” and expects to end the financial year in a solid leverage position, enabling continued investment alongside the return of excess capital to shareholders. The stock climbed 3.3%.

Mining shares dragged on the index as precious metals retreated sharply from recent highs. Spot gold declined more than 5% to $5,061, while spot silver tumbled over 11% to roughly $102.11. Endeavour Mining slumped 5.9%, Fresnillo dropped 5.5% and Antofagasta declined 4.3%.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

Smith & Nephew and Lloyds Banking Group were among the other notable risers, up 2.4% and 2.3% respectively.

AAF shares were down 3.2% after the company reported third-quarter results, with revenues of $4,667 million, a 24.6% increase in constant currency and 28.3% in reported terms.

The firm said strong strategic execution lifted constant currency revenue growth to 24.7% for the quarter, with currency appreciation pushing reported growth to 32.9%.

In the pharmaceutical sector, AstraZeneca said it had strengthened its weight-management portfolio through a new strategic collaboration with China’s CSPC Pharmaceuticals.

The agreement covers the development of multiple next-generation therapies for obesity and type 2 diabetes across eight programs.